180 related articles for article (PubMed ID: 25194443)
1. Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients.
Sakr SA; Abdel-Wahed MM; El-Sahra DG
Biomed Pharmacother; 2014 Jul; 68(6):685-92. PubMed ID: 25194443
[TBL] [Abstract][Full Text] [Related]
2. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
4. Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
Osunkoya AO; Epstein JI
Am J Surg Pathol; 2007 Sep; 31(9):1323-9. PubMed ID: 17721186
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
6. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
Xiao GQ; Burstein DE; Miller LK; Unger PD
Arch Pathol Lab Med; 2006 Jun; 130(6):805-10. PubMed ID: 16740031
[TBL] [Abstract][Full Text] [Related]
8. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
9. Pseudopapillary features in prostatic adenocarcinoma mimicking urothelial carcinoma: a diagnostic pitfall.
Gordetsky J; Epstein JI
Am J Surg Pathol; 2014 Jul; 38(7):941-5. PubMed ID: 24503758
[TBL] [Abstract][Full Text] [Related]
10. Prostatic adenocarcinoma with urothelial (transitional cell) carcinoma features.
Mai KT; Collins JP; Veinot JP
Appl Immunohistochem Mol Morphol; 2002 Sep; 10(3):231-6. PubMed ID: 12373149
[TBL] [Abstract][Full Text] [Related]
11. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
12. Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
Martínez-Rodríguez M; Ramos D; Soriano P; Subramaniam M; Navarro S; Llombart-Bosch A
Int J Surg Pathol; 2007 Apr; 15(2):213-8. PubMed ID: 17478786
[TBL] [Abstract][Full Text] [Related]
13. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
14. Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature.
Knez VM; Barrow W; Lucia MS; Wilson S; La Rosa FG
J Med Case Rep; 2014 Aug; 8():275. PubMed ID: 25124389
[TBL] [Abstract][Full Text] [Related]
15. Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate.
Ud Din N; Qureshi A; Mansoor S
Indian J Pathol Microbiol; 2011; 54(1):59-62. PubMed ID: 21393879
[TBL] [Abstract][Full Text] [Related]
16. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.
Varinot J; Cussenot O; Roupret M; Conort P; Bitker MO; Chartier-Kastler E; Cheng L; Compérat E
Virchows Arch; 2013 Dec; 463(6):803-9. PubMed ID: 24146108
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
18. Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma.
Oh WJ; Chung AM; Kim JS; Han JH; Hong SH; Lee JY; Choi YJ
J Pathol Transl Med; 2016 Sep; 50(5):345-54. PubMed ID: 27498545
[TBL] [Abstract][Full Text] [Related]
19. Expression of alpha-methylacyl-CoA racemase (P504S) in nephrogenic adenoma: a significant immunohistochemical pitfall compounding the differential diagnosis with prostatic adenocarcinoma.
Skinnider BF; Oliva E; Young RH; Amin MB
Am J Surg Pathol; 2004 Jun; 28(6):701-5. PubMed ID: 15166661
[TBL] [Abstract][Full Text] [Related]
20. Integrated immunohistochemical and molecular analysis improves diagnosis of high-grade carcinoma in the urinary bladder of patients with prior radiation therapy for prostate cancer.
Chan E; Garg K; Stohr BA
Mod Pathol; 2020 Sep; 33(9):1802-1810. PubMed ID: 32313185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
